R2 Nivi Arora has had a busy few weeks. She recently published this JAMA Internal Medicine Teachable moment recommending against broad upfront ANA sub-serology testing, especially without a positive ANA.
She now has a first-author review paper, titled ”Biological agents in gastrointestinal cancers: adverse effects and their management” published in the Journal of Gastrointestinal Oncology.
Take home points:
Anti VEGF agents—bevacizumab, aflibercept and ramucirumab: renal (proteinuria) and vascular complications (hypertension, thrombosis, GI perforations)
Anti EGFR agents – cetuximab and panitumumab: dermatological toxicity (acne, papulopustular lesions) and hypomagnesemia
Congratulations Nivi !!